Achilles Therapeutics company

Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer. The company's immunotherapies harness the immune system to destroy cancer cells that target truncal tumor neo-antigens and flags to the immune system present on the surface of every cancer cell, enabling scientists to target and destroy tumors without harming healthy tissues.
Technology: P4 Medicine
Industry: Biotechnology, Health Care, Science and Engineering
Headquarters: Stevenage, Herefordshire, United Kingdom
Founded Date: 2016-05-01
Employees Number: 1-10
Funding Status: Early Stage Venture
Investors Number: 11
Total Funding: £113.2M
Estimated Revenue: $10M to $50M
Last Funding Type: Series B

Visit Website
info@achillestx.com
https://twitter.com/achillestx
Register and Claim Ownership